Antiproteinuric and anti-inflammatory effects of thiazolidinedione

Nephrology

Volumn 13, Issue 1, 2008, Pages 53-57

  Szeto, Cheuk Chun ^a   Li, Philip Kam Tao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Inflammation; PPAR agonist; Proteinuria; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIPIZIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DRUG ACTIVITY; DRUG EFFECT; HEMODYNAMICS; HUMAN; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; LIGANDS; PROTEINURIA; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 38149021580     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00900.x     Document Type: Review

References (56)

1. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 2004 351 : 1106 18.
2. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 2001 60 : 14 30.
3. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am. J. Physiol. 1997 273 : F1013 22.
4. Yang T, Michele DE, Park J et al. Expression of peroxisome proliferator-activated receptors and retinoid X receptors in the kidney. Am. J. Physiol. 1999 277 : F966 73.
5. Ishizuka T, Ito O, Tan L et al. Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. Hypertens Res. 2003 26 : 929 36.
6. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 2001 134 : 61 71.
7. Izzedine H, Launay-Vacher V, Buhaescu I, Heurtier A, Baumelou A, Deray G. PPAR-gamma-agonists' renal effects. Minerva Urol. Nefrol. 2005 57 : 247 60.
8. Yoshimoto T, Naruse M, Nishikawa M et al. Anti-hypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am. J. Physiol. 1997 272 : E989 96.
9. Verma S, Bhanot S, Arakawa E, Yao L, Mcneill JH. Direct vaso-depressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 1998 56 : 7 16.
10. Nishimoto Y, Tomida T, Matsui H, Ito T, Okumura K. Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats. Hypertension 2002 40 : 190 94.
11. Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am. J. Physiol. 2005 289 : F442 50.
12. Arima S, Kohagura K, Takeuchi K et al. Biphasic vasodilatador action of troglitazone on the renal microcirculation. J. Am. Soc. Nephrol. 2002 13 : 342 9.
13. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 1998 338 : 867 72.
14. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 2001 134 : 61 71.
15. Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J. Cardiovasc. Pharmacol. 2004 44 : 215 22.
16. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res. Clin. Prac. 2005 70 : 20 25.
17. Sarafidis PA, Lasaridis AN, Nilsson PM et al. The effect of rosiglitazone on novel athero-sclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005 54 : 1236 42.
18. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. 2004 29 : 11 17.
19. Wakino S, Hayashi K, Tatematsu S et al. Pioglita-zone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res. 2005 28 : 255 62.
20. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005 54 : 2206 11.
21. Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW. Effects of ciglitazone on blood pressure and intra-cellular calcium metabolism. Hypertension 1993 21 : 1020 23.
22. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000 49 : 1022 32.
23. Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: Activation of the DAG-PKC-ERK pathway. Am. J. Kidney Dis. 2001 38 (Suppl. 1 S178 81.
24. Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002 51 : 403 8.
25. Sarafidis PA, Lasaridis AN, Nilsson PM et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am. J. Hypertens. 2005 18 : 227 34.
26. Ruilope LM, Bakris GL, McMorn SO et al. Rosiglitazone added to metformin reduces urinary albumin/creatinine ratio and ambulatory blood pressure in subjects with microalbuminuria and type 2 diabetes. 41st Annual Meeting of The European Association for the Study of Diabetes. Athens. September 2005, p779 A283.
27. Sung BH, Izzo JL Jr, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999 34 : 83 8.
28. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Cir Res. 1998 83 : 1097 103.
29. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPAR-gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 1999 19 : 546 51.
30. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998 47 : 810 14.
31. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J. Pharmcol. Exp. Ther. 2004 308 : 426 33.
32. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Nat. Acad. Sci. U.S.A. 2005 102 : 9406 11.
33. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-γ activated receptor is a negative regulator of macrophage activation. Nature 1998 391 : 79 82.
34. Jiang C, Ting AT, Seed B. PPAR-agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 391 : 82 6.
35. Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci. 2003 19 : 553 62.
36. Majithiya JB, Parmar AN, Trivedi CJ, Balaraman R. Effect of pioglitazone on 1-NAME induced hypertension in diabetic rats. Vasc. Pharmacol. 2005 43 : 260 66.
37. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004 53 : 200 208.
38. Maeda A, Horikoshi S, Gohda T, Tsuge T, Maeda K, Tomino Y. Pioglitazone attenuates TGF-beta (1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR) -gamma. Cell Biol. Int. 2005 29 : 422 8.
39. Dong FQ, Li H, Cai WM et al. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin. Med. J. 2004 117 : 1040 44.
40. Zafiriou S, Stanners SR, Polhill TS, Poronnik P, Pollock CA. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int. 2004 65 : 1647 53.
41. Onozaki A, Midorikawa S, Sanada H et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: Inhibitory effects of thiazolidinedione. Biochem. Biophys. Res. Commu. 2004 317 : 24 9.
42. Xiong Z, Huang H, Li J, Guan Y, Wang H. Anti-inflammatory effect of PPARgamma in cultured human mesangial cells. Ren. Fail. 2004 26 : 497 505.
43. Ueta M, Wakisaka M, Ago T et al. PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose. Kidney Int. 2004 65 : 961 71.
44. Gruden G, Setti G, Hayward A et al. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: Inhibition by rosiglitazone. J. Am. Soc. Nephrol. 2005 16 : 688 96.
45. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004 53 : 1473 9.
46. Nakamura T, Matsuda T, Kawagoe Y et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004 53 : 1382 6.
47. Agarwal R, Saha C, Battiwala M et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005 68 : 285 92.
48. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J. Hum. Hypertens. 2003 17 : 7 12.
49. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001 50 : 1193 6.
50. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CWK, Li PKT. Rosiglitazone (RSG) reduces Insulin requirement and C-reactive protein levels in Type 2 diabetic patients on peritoneal dialysis. Am. J. Kidney Dis. 2005 46 : 713 19.
51. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol. 2003 42 : 1757 63.
52. Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (in press).
53. Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet 2006 368 : 555 6.
54. Li PK, Leung CB, Chow KM et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am. J. Kidney Dis. 2006 47 : 751 60.
55. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004 27 : 256 63.
56. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007 356 : 2457 71.